Hier bieten wir Ihnen einen Überblick zu Studien zum Thema Gebärmutterhalskrebsvorsoge:

Arbyn, M. Bergeron, C. Klinkhamer, P. et al.: Liquid Compared With Conventional Cervical Cytology. in: Obstetrics & Gynecology, 2008, 111(1): 167-77 (http://www.ag-cpc.de/media/Arbyn-Obstet%20Gynecol2008.pdf)

Becker, N.: Epidemiological aspect of cancer screening in Germany. in: Journal of Cancer Research and Clinical Oncology, 14.03.2003; Springer-Verlag, 2003. 129. S. 691-702. DOI 10.1007/s00432-003-0494-y

Blatt, AJ., Kennedy, R., Luff, RD., Austin, RM., Rabin, DS.: Comparison of cervical cancer screening results among 256,684 women in multiple clinical practices. in: Cancer Cytopathol, 2015; 123(5): 282-8, (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654274/)

Bornstein, J., Bentley, J., Bösze, P., Girardi, F. et al.: Colposcopic Terminology of the International Federation for Cervical Pathology and Colposcopy.in: Obstetrics & Gynecology,2012; 120(1): 166-72

Dudding, N., Cossley, J.: Sensitivity and specificity of HPV testing: what are the facts? in: Cytopathology, 2013; 24: 283-8 (nicht kostenfrei verfügbar), (http://onlinelibrary.wiley.com/doi/10.1111/cyt.12104/abstract)

Fitzgerald, P., Cox, B., Miller, A., Hall, S., Reid, J.: The proposed change to primary HPV screening in New Zealand: reasons for caution. in: New Zealand Medical Journal, 2016, 129(1431): S. 18-22 (http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2016/vol-129-no-1431-11-march-2016/6827) University of Otago: Caution urged over planned introduction of new cervical screening test. 11.03.2016; (http://www.otago.ac.nz/news/news/otago597623.html)

Haedicke, J. Iftner, T.: A review of the clinical performance of the Aptima HPV assay. in: Journal of Clinical Virology, 2016, 76: 40-48

Herbert, A.: Primary HPV testing: a proposal for co-testing in initial rounds of screening to optimise sensitivity of cervical cancer screening. in: Cytopathology, 2016: 1-7

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG): Rapid Report 13-03, Version 1.0, HPV-Test im Primärscreening des Zervixkarzinoms 14.05.2014

Katki, HA., Kinney, WK., Fetterman, B., Lorey, T., Poitras, NE., Cheung, L., Demuth, F., Schiffman, M., Wacholder, S., Castle, PE.: Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice at a large managed care organization. in: Lancet Oncology 2011; 12: 663-72 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272857/)

Kinney, W., Wright, TC., Dinkelspiel, HE., DeFrancesco, M., Cox, JT., Huh, W.: Increased cervical cancer risk associated with screening at longer intervals. in: Obstetrics & Gynecology, 2015; 125: 311-5 (nicht kostenfrei verfügbar), (http://www.ncbi.nlm.nih.gov/pubmed/25568989)

Klug, SJ. Neis, KJ. Harflinger W. et al.: A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. in: International Journal of Cancer, 2012, 132: 2849-57 (http://onlinelibrary.wiley.com/doi/10.1002/ijc.27955/pdf)

Lütge, M. Weiterentwicklung des Zervixkarzinom-Screenings – Wie wird die zukünftige Strategie aussehen? in: Gynäkologie + Geburtshilfe. 2016, 21(2), 38-9

Malila, N., Leinonen, M., Kotaniemi-Talonen, L., Lauril, P., Tarkanen, J., Hakam, M. (2012): The HPV test has similar sensitivity but more overdiagnosis than the Pap test – A randomised health services study on cervical cancer screening in Finland. in: International Journal of Cancer. 132, S. 2141-2147 (2013). Doi. 10.1002/ijc.27850 Quest diagnostics weighs in on HPV test as first-line cervical cancer screen. The PATHOLOGY BLAWG. [Last accessed on 2014 Mar 12]. (http://www.pathologyblawg.com/pathology-news/pathology-vendors/quest-diagnostics/quest-diagnostics-weighs-in-hpv-test-first-line-cervical-cancer-screen/)

Marquardt, K., Stubbe, M., Broschewitz, U.: Zervixkarzinome in Mecklenburg-Vorpommern. in: Pathologe 2016; 1: S. 78-83

Pirog, EC. et al.: HPV prevalence and genotypes in different histological subtypes of cervical adeno-carcinoma, worldwide analysis of 760 cases. in: Modern Pathology, 2014; 27, 1559-76

Rebolj, M., Preisler, S., Ejegod, D. M., Rygaard, C., Lynge, E.: Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening. in: PLoS ONE 9(1): e86835. DOI:10.1371/journal.pone.0086835. 2014

Rijkaart, DC., Berkoff, J., Rozendaal, L., van Kemenade, FJ., Bulkmans, NW., Heideman, DA., Kenter, GG., Cuzick, J., Snijders, PJ., Meijer, CJ.: Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. in: Lancet Oncology, 2012; 13: S. 78-88 (http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2811%2970296-0/fulltext)

Siebert, U., Sroczynski, G., Hillemanns, P., Engel, J., Stabenow, R., Stegmaier, C., Voigt, K., Gibis, B., Hölzel, D., Goldie, SJ.: The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany, in: Euro Journal Public Health. 16.04.2006, (2): S. 185-92. (http://www.ncbi.nlm.nih.gov/pubmed/16469759), Epub, veröffentlicht: 09.02.2006

Stoler, MH., Austin, RM., Zhao, C.: Point-Counterpoint: Cervical cancer screening should be done by primary human papillomavirus testing with genotyping and reflex cytology for women over the age of 25 years. in: Journal of Clinical Microbiology, 2015; 53: S. 2798-2804 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540928/)

Sundström, K., Ploner, A., Dahlström, LA., Palmgren, J., Dillner, J., Adami, HO., Ylitalo, N., Sparén, P.: Prospective study of HPV16 viral load and risk of in situ and invasive squamous cervical cancer. in: Cancer Epidemiol Biomarkers & Prevention, 2013; 22: 150-8 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538961/)

Tao, X., Griffith, CC., Zhou, X., Wang, Z., Yan, Y., Li, Z., Zhao, C.: History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women’s hospital in China. in: Cancer Cytopathol, 2015; 123:421-7 (http://onlinelibrary.wiley.com/doi/10.1002/cncy.21545/abstract)

Van Hagenem, N. et. al.: Fertility-sparing treatment in younger women with adenocarcinoma in situ of the cervix. in: Gynecologic Oncology, 2012; 24: 72-7

Westin, Shannon N.; Bustillos, Dan; Gano, Jacalyn B.; Fields, Margaret M.; Coker, Ann L.; Sun, Charlotte C.; and Ramondetta, Lois M., „Social Factors Affecting Treatment of Cervical Cancer: Ethical Issues and Policy Implications“ (2008). in: CRVAW Faculty Journal Articles. Paper 139.

Won, K-H., Lee, JY., Suh DH., No JH, Kim Y-B.: Impact of age on false negative rate of human papillomavirus DNA test in patients with atypical squamous cells of undetermined significance. Obstetrics & Gynecology Science, 2015; 58: 117-23 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366864/)

Zheng, B., Li, Z., Griffith, CC., Yan, S., Chen, C., Ding, X., Liang, X., Yang, H., Zhao, C.: Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China’slargest CAP-certified laboratory. in: Cancer Cytopathol 2015; 123: 428-34 (http://onlinelibrary.wiley.com/doi/10.1002/cncy.21557/abstract)

  • Expertengruppe

    Lebensläufe, Positionen, Fotos
  • Kontakt